MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer

June 3-7, 2016; Chicago, Illinois
This study conducted by the Canadian Cancer Trials Group is the first to show that extending aromatase inhibitor therapy beyond 5 years reduces the risk of disease recurrence.
Format: Microsoft PowerPoint (.ppt)
File Size: 565 KB
Released: June 7, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Experts provide their thoughts on key data in breast and gynecologic cancers from the 2022 ASCO Annual Meeting, from Clinical Care Options (CCO)

Joyce O'Shaughnessy, MD Angeles Alvarez Secord, MD, MHSc Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: August 17, 2022 Expired: August 16, 2023

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Commentary from Dr Heather McArthur on latest developments in managing early-stage breast cancer (EBC), from Clinical Care Options (CCO)

Heather McArthur, MD, MPH
Program Director
Released: August 4, 2022

Downloadable slideset from a live webinar presented by Sarah Hurvitz, MD, on selecting and sequencing targeted therapy for HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Released: July 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings